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ABSTRACT
Aims: EGFR and ALK analysis is routinely undertaken prior to targeted treatment of
non-squamous non-small cell lung carcinoma (NSCLC). Increasingly limited
resources require molecular pathology services to be cost effective without detriment
to patient care.
Methods: Data from an audit of molecular pathology testing in the South East of
Scotland Cancer network has been used to explore different testing strategies with the
aim of reducing costs; including investigation of TTF1 expression as a negative
predictor for EGFR mutations.
Results: TTF1 immunohistochemistry had a high negative predictive value for EGFR
mutations (99%). Reflex testing all non-squamous NSCLC had the highest costs
whereas limiting testing to those who might be considered for treatment would save
7.5%; the serial model could save 32.7%.
Conclusions: Testing only patients being considered for EGFR and ALK inhibitors
represented small savings; more significant savings would be achievable if testing
algorithms utilized known associations between clinical biomarkers.
INTRODUCTION
Current UK and USA recommendations for the treatment of locally advanced or
metastatic non-squamous non-small cell lung cancer (non-squamous NSCLC) include
first line EGFR tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) for
tumours with activating EGFR mutations; and ALK inhibitors (crizotinib and
ceritinib) for previously treated patients whose tumours harbour ALK gene
rearrangements.1-3 As a result, predictive EGFR mutation analysis has been carried
out by clinical laboratories since 2009 and in 2013 ALK rearrangement analysis was
added to the testing algorithm. Studies have shown that in a Caucasian population
approximately 10% of NSCLC have EGFR mutations,4 2 to 5% have ALK
rearrangements,5 and 35% have KRAS mutations.6 Although there is no direct
therapeutic value in the detection of somatic KRAS mutations it is performed in many
laboratories carry as KRAS mutations are, in the vast majority of samples, mutually
exclusive with EGFR and ALK mutations.7
Thyroid transcription factor 1 (TTF1) has, for many years, been used as an
immunohistochemical marker to aid the diagnosis of lung adenocarcinoma.
Approximately 80% of non-squamous NSCLC requested for molecular pathology
testing show positive nuclear staining with TTF1 antibodies.8 Several studies have
shown a correlation between TTF1 protein expression and the presence of EGFR
mutations (see table 1), indeed TTF1 IHC has been shown to be a good negative
predictor of EGFR mutations in western populations; however, this association
appears to be less strong in East Asian populations.
Table 1: Studies comparing TTF1 IHC with the presence of EGFR mutations
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Vallee et al. 8 1038 79.0% 3 98.6% France
Vincenten et al. 9 797 67.9% 9 96.5% Netherlands
Krawczyk et al. 10 727 80.4% 10 93.0% Poland
Chatziandreou et al. 11 595 70.4% 2 98.9% Greece
Sheffield et al. 12 306 77.1% 4 94.3% Canada
Somaiah et al. 13
(pilot and validation)
301 90% 2 93.3% America
131 72.5% 1 97.2% America
Leary et al. 14 70 78.6% 0 100% Britain
Zhang et al. 15 1042 87.2% 50 62.4% China
Shanzhi et al. 16 660 98.5% 1 90% China
Chung et al. 17 496 89.3% 17 67.92% Taiwan
Sun et al. 18 190 79.5% 6 84.6% Korea
Yatabe et al. 19 95 57.9% 7 82.5% Japan
There is still debate as to the best approach for molecular pathology testing of lung
cancers; some laboratories favour testing all patients with a histologically or
cytologically diagnosed non-squamous non-small cell lung cancer, whereas others test
only samples from patients being considered for EGFR or ALK targeted therapy.
Although a request based model may require rapid turnaround times in order to meet
the clinical need it would be likely to reduce costs by avoiding testing unnecessary
cases. This report explores options for improving cost efficiency in lung cancer
molecular pathology without impacting patient care.
METHODS
The pathology laboratory based at the Royal Infirmary of Edinburgh provides
molecular testing in lung cancer for the South East of Scotland cancer network
covering NHS Lothian, NHS Borders, NHS Fife and NHS Dumfries and Galloway. A
clinical audit was carried out of lung cancer Molecular Pathology requests across the
network between January 2011 and March 2014. After histopathology assessment and
macrodissection (as required) DNA was extracted from FFPE tissue using the
QIAamp DNA FFPE tissue Kit (Qiagen). EGFR mutation analysis was carried out
using the Therascreen EGFR RGQ PCR kit (Qiagen); mutations in KRAS codons 12,
13 and 61 were detected using an in-house Pyrosequencing assay. Samples requiring
ALK rearrangement analyses were initially screened for ALK protein expression by
immunohistochemistry (IHC) using the D5F3 clone (1 in 200 dilution) on a Bond-III
system (Leica, UK). Samples positive by ALK IHC were tested for ALK gene
rearrangements by fluorescence in situ hybridisation (FISH) using the Vysis ALK
Break Apart FISH Probe Kit (Abbott Molecular). Pearson’s chi-squared test and
Fisher’s Exact test were used to explore associations between clinicopathological and
molecular parameters. TTF1 IHC was performed, if not already carried out for
histological diagnosis, on samples with EGFR mutations. TTF1 IHC was performed
on a Bond-III using the 8G7G3/1 antibody (M3575, Dako) with 20 minutes retrieval
and Leica solution ER2. Sections stained with TTF1 were assessed for the presence of
any nuclear staining by a consultant histopathologist specialising in respiratory
pathology.
The number and diagnoses of all lung cancer patients registered in the Borders,
Dumfries & Galloway, Fife and Lothian Health Boards between April 2013 and
March 2014 were supplied by the South East Scotland Cancer Network (SCAN).
These data, and the results of the clinical audit, were used to develop models of
testing using four algorithms. 1. In the reflex model samples from all patients
diagnosed with non-squamous NSCLC, regardless of intention to treat with EGFR or
ALK targeted therapies, would be simultaneously tested for EGFR, KRAS and ALK
mutations. 2. In the request model only samples from patients with metastatic or
locally advanced (stage III and IV) non-squamous NSCLC, i.e. those eligible for
treatment with EGFR TKIs or ALK inhibitors, would be simultaneously tested for
EGFR, KRAS and ALK mutations. 3. The serial testing model was designed to utilise
the mutually exclusive relationship between EGFR, KRAS and ALK mutations in
order to minimise testing. All patients eligible for targeted therapy would be tested for
KRAS mutations; only those with no mutations would have EGFR mutation analysis
and only samples with no KRAS or EGFR mutations would have ALK rearrangement
analysis. 4. Finally, in the TTF1-serial model all patients eligible for targeted therapy
would be initially tested for TTF1 and ALK rearrangements; given the limited data
available this model does not assume a correlation between TTF1 expression and ALK
rearrangements. Only TTF1 positive ALK negative samples would have KRAS
mutation analysis and only those with no KRAS mutations would be tested for EGFR
mutations. The cost of testing using each model was estimated using the CMD Impact
Business Planning Tool developed by the Royal College of Pathologists, Cancer
Research UK and the Association of the British Pharmaceutical Industry
(https://www.rcpath.org/cmd-impact.html). The estimated annual cost of each model
was represented as a proportion of the cost of the request model.
RESULTS
Between January 2011 and March 2014 there were 710 requests for lung cancer
molecular pathology testing; of those suitable for testing 10.5% had EGFR mutations,
36.5% had KRAS mutations, 2.3% had ALK gene rearrangements, and 79.4% showed
positive staining for TTF1. No samples were found to have co-occurring EGFR,
KRAS or ALK mutations. Although positive TTF1 IHC was not predictive for the
presence of EGFR mutations (positive predictive value 13.4%, n= 461) no samples
with EGFR mutations were negative for TTF1expression. After additional TTF1 IHC
117 specimens with EGFR mutations were positive for TTF1 nuclear staining and 1
showed only cytoplasmic staining and was therefore considered negative; equating to
a negative predictive value (NPV) of 99.05%
Four hundred patients with histopathology/ cytopathological samples were diagnosed
with adenocarcinoma or non-small cell lung carcinoma between April 2013 and
March 2014; of those 370 were stage III or IV and therefore eligible for EGFR TKI or
ALK inhibitor therapy. Based on these figures, the annual cost of lung cancer
molecular pathology testing by the request model was estimated to be 92.5% of that of
the reflex model. Testing by the serial model was estimated to cost only 67.3% of the
request model. If TTF1 were fully validated as a negative predictive biomarker the
cost of testing could be reduced to 62.5% of the reflex model (summarised in table 2).
Table 2: Summary of models
Model Cohort Tests carried out Cost relative
to reflex
model
Reflex All non-squamousNSCLC EGFR, ALK & KRAS
simultaneously
100%
Request
Stage III or IV non-
squamous NSCLC
92.5%
Serial
KRAS;
KRAS neg > EGFR;
KRAS & EGFR neg > ALK
67.3%
TTF1-
serial
TTF1 & ALK;
TTF1 pos & ALK neg > KRAS;
TTF1 pos & KRAS neg > EGFR
62.5%
Neg= no mutation detected, Pos= positive expression of protein
DISCUSSION
In our cohort TTF1 IHC had a high negative predictive value (NPV) for EGFR
mutations supporting the association previously reported in several studies with
Caucasian populations,8 9 11 14 although this correlation seems to be weaker in East
Asian populations.15 17-19 Two studies used a scoring system to determine TTF1 status
which may have reduced the number of positive samples and therefore lowered the
NPV.9 18 Our study was carried out in a clinical diagnostic setting and any nuclear
staining, even focal staining, was considered positive for TTF1. One sample from a
total of 118 EGFR mutation positive patients showed only cytoplasmic staining with
the TTF1 antibody; upon further investigation this biopsy, which had a p.(Gly719X)
EGFR mutation, was taken post chemo-radiation. A previous specimen taken pre-
treatment was TTF1 positive, however since several years had elapsed between the
two samples it was not possible to determine if the latter biopsy was a recurrence or a
second primary tumour. Unfortunately, there was too little tissue remaining in the pre-
treatment sample to perform EGFR mutation analysis.
Many clinical laboratories are experiencing increasing pressures to reduce costs;
where funding is restricted algorithms must supply the most cost effective use of
limited resources without compromising clinical utility and the welfare of patients.
The saving represented by only testing patients eligible for treatment with targeted
therapies (the request model) would be easily achievable in most clinical laboratories
without any detrimental effect on patient care; a proposal supported by data from
another institution.20 In reality NHS Lothian employs a system between the reflex and
request models and accepts requests from oncologists if a patient is being considered
for treatment or from histopathologists if the diagnostic sample confirms distant
metastatic disease.
Currently there is no direct therapeutic impact of KRAS nevertheless KRAS mutation
status in non-squamous NSCLC does have some value, since a large proportion of
tumours carry mutations their detection ensures, particularly in samples with a low
proportion of neoplastic cells, that the appropriate tissue has been tested. Withdrawing
KRAS analysis would reduce costs by 18% compared to the reflex model. However,
stratifying the cohort using the serial model, including KRAS analysis, would allow a
much greater saving; a 32.7% reduction compared to the reflex model. Laboratories
whose primary method is a multiplex assay, for example next generation sequencing
(NGS), would not benefit from the serial model; but for many labs NGS is not an
option and will, for the foreseeable future, continue to carry out single genes analyses.
The value of TTF1 IHC may not be limited to cost efficiency, if an initial specimen
was considered insufficient for molecular analysis the TTF1 status may help
determine the value of subjecting a patient to a procedure to obtain a repeat sample.
Although promising there is, as yet, too little data on the association between TTF1
IHC and EGFR to fully support its use as a negative predictor for EGFR mutations.
Further audits by molecular pathology laboratories could elucidate this relationship
and help confirm or refute the use of this readily available histopathology biomarker
as a screening tool prior to EGFR mutation analysis.
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